ARC-sparX
Platform
Arcellx is developing a uniquely adaptable and controllable cell therapy.
Our Technology
Arcellx is developing a uniquely adaptable and controllable cell therapy.
The Arcellx platform has two key components: sparX proteins and universal ARC-T cells. sparX proteins bind to specific antigens on diseased cells, then flag those cells for destruction by ARC-T cells. SparX proteins contain novel binding domains that recognize specific disease-associated antigens. Arcellx is developing a collection of sparX proteins to treat a range of diseases. ARC-T cells are engineered immune cells that bind to sparX proteins and kill the flagged cells. ARC-T cells, which cannot recognize diseased cells on their own, activate only when combined with a sparX protein bound to an antigen on a cell. ARC-T cells are equipped with a novel binding domain designed to recognize the universal tag portion of sparX proteins. The tag binding domain on every ARC-T cell is built on a domain scaffold shared with the antigen binding domains in sparX proteins.